272 related articles for article (PubMed ID: 33754068)
1. Intratumor heterogeneity of breast cancer detected by epialleles shows association with hypoxic microenvironment.
Wang Y; Zhang Y; Huang Y; Chen C; Zhang X; Xing Y; Gu Y; Zhang M; Cai L; Xu S; Sun B
Theranostics; 2021; 11(9):4403-4420. PubMed ID: 33754068
[No Abstract] [Full Text] [Related]
2. Intratumor heterogeneity index of breast carcinomas based on DNA methylation profiles.
Campoy EM; Branham MT; Mayorga LS; Roqué M
BMC Cancer; 2019 Apr; 19(1):328. PubMed ID: 30953488
[TBL] [Abstract][Full Text] [Related]
3. Hyper-methylation of the upstream CpG island shore is a likely mechanism of GPER1 silencing in breast cancer cells.
Manjegowda MC; Gupta PS; Limaye AM
Gene; 2017 May; 614():65-73. PubMed ID: 28286086
[TBL] [Abstract][Full Text] [Related]
4. Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter.
Poli E; Zhang J; Nwachukwu C; Zheng Y; Adedokun B; Olopade OI; Han YJ
PLoS One; 2015; 10(11):e0142224. PubMed ID: 26539832
[TBL] [Abstract][Full Text] [Related]
5. The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability.
Derrien J; Guérin-Charbonnel C; Gaborit V; Campion L; Devic M; Douillard E; Roi N; Avet-Loiseau H; Decaux O; Facon T; Mallm JP; Eils R; Munshi NC; Moreau P; Herrmann C; Magrangeas F; Minvielle S
Genome Med; 2021 Aug; 13(1):127. PubMed ID: 34372935
[TBL] [Abstract][Full Text] [Related]
6. DNA ligase-based strategy for quantifying heterogeneous DNA methylation without sequencing.
Wee EJ; Rauf S; Shiddiky MJ; Dobrovic A; Trau M
Clin Chem; 2015 Jan; 61(1):163-71. PubMed ID: 25274555
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-induced changes in intragenic DNA methylation correlate with alternative splicing in breast cancer.
Pant D; Narayanan SP; Vijay N; Shukla S
J Biosci; 2020; 45():. PubMed ID: 31965981
[TBL] [Abstract][Full Text] [Related]
8. Specific breast cancer prognosis-subtype distinctions based on DNA methylation patterns.
Zhang S; Wang Y; Gu Y; Zhu J; Ci C; Guo Z; Chen C; Wei Y; Lv W; Liu H; Zhang D; Zhang Y
Mol Oncol; 2018 Jun; 12(7):1047-1060. PubMed ID: 29675884
[TBL] [Abstract][Full Text] [Related]
9. The relevance between hypoxia-dependent spatial transcriptomics and the prognosis and efficacy of immunotherapy in claudin-low breast cancer.
Sun H; Li Y; Zhang Y; Zhao X; Dong X; Guo Y; Mo J; Che N; Ban X; Li F; Bai X; Li Y; Hao J; Zhang D
Front Immunol; 2022; 13():1042835. PubMed ID: 36685583
[TBL] [Abstract][Full Text] [Related]
10. Multi-omics analysis elucidates the relationship between intratumor microbiome and host immune heterogeneity in breast cancer.
Li J; Zhang Y; Cai Y; Yao P; Jia Y; Wei X; Du C; Zhang S
Microbiol Spectr; 2024 Apr; 12(4):e0410423. PubMed ID: 38442004
[TBL] [Abstract][Full Text] [Related]
11. Solute carrier family 16 member 5 downregulation and its methylation might serve as a prognostic indicator of prostate cancer.
Meng X; Yuan H; Li W; Xiong Z; Dong W; Xiao W; Zhang X
IUBMB Life; 2021 Nov; 73(11):1363-1377. PubMed ID: 34549875
[TBL] [Abstract][Full Text] [Related]
12. Large-scale analysis of
Croes L; Beyens M; Fransen E; Ibrahim J; Vanden Berghe W; Suls A; Peeters M; Pauwels P; Van Camp G; Op de Beeck K
Clin Epigenetics; 2018; 10():51. PubMed ID: 29682089
[TBL] [Abstract][Full Text] [Related]
13. Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
Böck J; Appenzeller S; Haertle L; Schneider T; Gehrig A; Schröder J; Rost S; Wolf B; Bartram CR; Sutter C; Haaf T
Int J Cancer; 2018 Sep; 143(6):1416-1425. PubMed ID: 29659014
[TBL] [Abstract][Full Text] [Related]
14. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
[TBL] [Abstract][Full Text] [Related]
15. Clonal intratumor heterogeneity of promoter hypermethylation in breast cancer by MS-MLPA.
Moelans CB; de Groot JS; Pan X; van der Wall E; van Diest PJ
Mod Pathol; 2014 Jun; 27(6):869-74. PubMed ID: 24287456
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
[TBL] [Abstract][Full Text] [Related]
17. The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer.
Han YJ; Liu S; Hardeman A; Rajagopal PS; Mueller J; Khramtsova G; Sanni A; Ajani M; Clayton W; Hurley IW; Yoshimatsu TF; Zheng Y; Parker J; Perou CM; Olopade OI
Clin Cancer Res; 2024 Jun; 30(11):2609-2618. PubMed ID: 38564595
[TBL] [Abstract][Full Text] [Related]
18. Gene-Expression Profiling to Decipher Breast Cancer Inter- and Intratumor Heterogeneity.
Swarbrick A; Fernandez-Martinez A; Perou CM
Cold Spring Harb Perspect Med; 2024 Jan; 14(1):. PubMed ID: 37137498
[TBL] [Abstract][Full Text] [Related]
19. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation profiles capturing breast cancer heterogeneity.
Chen X; Zhang J; Dai X
BMC Genomics; 2019 Nov; 20(1):823. PubMed ID: 31699026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
